|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1993-7-26
|
|
pubmed:abstractText |
MVAC is considered the most effective chemotherapy regimen for transitional cell bladder carcinoma. However, due to its significant toxic effects we substituted carboplatin for cisplatin and epirubicin for adriamycin in an attempt to produce the same response with less toxicity.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
4
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
313-6
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:8518222-Aged,
pubmed-meshheading:8518222-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8518222-Carboplatin,
pubmed-meshheading:8518222-Carcinoma, Transitional Cell,
pubmed-meshheading:8518222-Epirubicin,
pubmed-meshheading:8518222-Female,
pubmed-meshheading:8518222-Humans,
pubmed-meshheading:8518222-Male,
pubmed-meshheading:8518222-Methotrexate,
pubmed-meshheading:8518222-Middle Aged,
pubmed-meshheading:8518222-Urinary Bladder Neoplasms,
pubmed-meshheading:8518222-Vinblastine
|
|
pubmed:year |
1993
|
|
pubmed:articleTitle |
Carboplatin, methotrexate, vinblastine and epirubicin (Carbo-MVE) for transitional cell bladder carcinoma.
|
|
pubmed:affiliation |
Bladder Cancer Committee, Clinic Hospital, School of Medicine, Barcelona University, Spain.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study
|
